{'fraction_non_alphanumeric': 0.022537562604340568, 'fraction_numerical': 0.009181969949916527, 'mean_word_length': 5.212435233160622, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Spironolactone—a weak enzyme inducer in man

half-life would have been expected. The finding of identical values in the chlorpromazine group and in the elderly drug-free patients clearly demonstrates that chlorpromazine has not increased drug-metabolizing capacity. This is further emphasized by the fact that the chlorpromazine group are appreciably younger than the elderly control patients and for this reason would be expected to be faster metabolizers of antipyrine (O’Malley & others, 1971). Possible reasons for the discrepancy between the present findings and those of Curry & others (1971) are, firstly, people in the age group of the chlorpromazine patients studied may not be inducible. A second possibility is that chlorpromazine may produce only weak induction in man. This degree of induction might be sufficient to reduce the steadystate plasma level of the drug when administered over a long period but not sufficiently great to affect measurably the plasma half-life of a concomitantly administered drug. Certainly, from our rat studies (Table 2) chlorpromazine while being an inducer, produced only 33% of the stimulation caused by barbitone and must be considered a weak inducer.